City Therapeutics, Inc. (CTY)
NASDAQ: CTY · Real-Time Price · USD
18.10
-0.88 (-4.64%)
At close: Nov 13, 2026, 4:00 PM EST
18.45
+0.35 (1.93%)
After-hours: Nov 13, 2026, 7:30 PM EST

City Therapeutics Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, City Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $37.33. The average 1-year stock price forecast is 106.24% higher than the current stock price, while the lowest is $32 (+76.80%) and the highest is $46 (+154.14%).

Price Target: $37.33 (+106.24%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$32$37.33$34$46
Change+76.80%+106.24%+87.85%+154.14%

Analyst Ratings

The average analyst rating for City Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingNov '26
Strong Buy3
Buy0
Hold0
Sell0
Strong Sell0
Total3

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Jefferies
Jefferies
Buy
Initiates
$32
BuyInitiates$32+76.80%Nov 10, 2026
Stifel Nicolaus
Stifel Nicolaus
Buy
Initiates
$34
BuyInitiates$34+87.85%Nov 10, 2026

Financial Forecast

Revenue This Year
22.10M
from 13.56M
Increased by 62.96%
Revenue Next Year
23.75M
from 22.10M
Increased by 7.47%
EPS This Year
-4.04
EPS Next Year
-3.03
from -4.04
Fiscal YearFY 2024FY 2025FY 2026
Period EndingDec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
2.78M13.56M22.10M
Revenue Growth
-388.19%62.96%
Operating Income
-29.09M-59.92M-99.16M
Net Income
-27.84M-58.51M-107.95M
EPS
---4.04
Free Cash Flow
---89.50M
No. Analysts
--4
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High30.0M
Avg22.1M
Low13.4M

Revenue Growth

Revenue Growth202620272028
High
121.2%
Avg
63.0%
Low
-1.2%

EPS Forecast

EPS202620272028
High-2.65
Avg-4.04
Low-6.66

EPS Growth

EPS Growth20272028
High-
Avg-
Low-